BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 05:09:11 01/07/2024 pm IST | ||
| 965.8 EUR | -0.15% |
|
| Current month | +6.71% | ||
| 1 month | +8.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 965.8 | -0.15% |
| 28/24/28 | 967.3 | +0.50% |
| 27/24/27 | 962.5 | -0.05% |
| 26/24/26 | 963 | +0.01% |
| 25/24/25 | 962.9 | +0.06% |
Real-time Boerse Frankfurt Warrants
Last update July 01, 2024 at 05:09 pm IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD423L |
| ISIN | DE000HD423L0 |
| Date issued | 22/03/2024 |
| Strike | 1,000 $ |
| Maturity | 20/12/2024 (172 Days) |
| Parity | 1 : 1 |
| Emission price | 839.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 967.5 € |
|---|---|
| Lowest since issue | 779.8 € |
| Spread | 1.04 € |
| Spread % | 0.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
